Who are CHLORTETRACYCLINE HYDROCHLORIDE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tygacil, Doxycycline post-exposure prophylaxis, Doxycycline (Oracea), Amikacin (Inhalation), Neomycin Oral Product, hand mixed tobramycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chlortetracycline-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CHLORTETRACYCLINE HYDROCHLORIDE — Competitive Intelligence Brief

CHLORTETRACYCLINE HYDROCHLORIDE (CHLORTETRACYCLINE HYDROCHLORIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline. Area: Infectious Disease.

marketed Tetracycline 30S ribosomal subunit Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

CHLORTETRACYCLINE HYDROCHLORIDE (CHLORTETRACYCLINE HYDROCHLORIDE). Chlortetracycline hydrochloride inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the ribosome.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CHLORTETRACYCLINE HYDROCHLORIDE TARGET	CHLORTETRACYCLINE HYDROCHLORIDE		marketed	Tetracycline	30S ribosomal subunit	1950-01-01
Tygacil	TIGECYCLINE	Fresenius Kabi	marketed	Tetracycline-class Antibacterial [EPC]	30S ribosomal subunit	2005-01-01
Doxycycline post-exposure prophylaxis	Doxycycline post-exposure prophylaxis	University of Washington	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Doxycycline (Oracea)	Doxycycline (Oracea)	LEO Pharma	marketed	Tetracycline antibiotic (anti-inflammatory formulation)	Matrix metalloproteinases (MMPs); 30S ribosomal subunit
Amikacin (Inhalation)	Amikacin (Inhalation)	The University of Queensland	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Neomycin Oral Product	Neomycin Oral Product	South Australian Health and Medical Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
hand mixed tobramycin	hand mixed tobramycin	Washington University School of Medicine	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-10-24 — Tygacil · 8975242 · US
2029-02-05 — Tygacil · 7879828 · US
2030-10-08 — Tygacil · 8372995 · US
2033-04-07 — Tygacil · 9855335 · US

Sponsor landscape (Tetracycline class)

· 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CHLORTETRACYCLINE HYDROCHLORIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/chlortetracycline-hydrochloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab